Polen Capital, an investment management company, released its “Polen Focus Growth Strategy” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. The U.S. equities have experienced a significant performance surge over the past two years.

A federal judge has effectively ended the ability of compounding pharmacies to make their own copies of Eli Lilly’s weight loss and diabetes drugs Zepbound and Mounjaro. In a sealed decision filed late Wednesday,

Pharmaceutical giant expects the move will create 3,000 high-skilled jobs and provide work for approximately 10,000 construction workers.

Eli Lilly, the maker of blockbuster weight loss and diabetes drugs Zepbound and Mounjaro, said it will invest an additional $27 billion to build four new manufacturing plants in the United States, shoring up domestic manufacturing as President Donald Trump threatens new tariffs on pharmaceuticals.

Eli Lilly and Co. is in negotiations with several states and plans to announce the locations of four new manufacturing plants later this year.

Teladoc Health teams up with Eli Lilly's LillyDirect to improve Zepbound access, offering direct home delivery and comprehensive obesity care support.

Eli Lilly announced plans for four new pharmaceutical manufacturing sites to produce domestic medicine production in the United States and make the nation the world's leader in pharmaceutical production.

While the Super Bowl may not always be the ideal spot for pharma, cultural events like the Oscars can offer a more appropriate opportunity for advertising.

Eli Lilly is partnering with Imagine Entertainment and MACRO to drive industry-wide change and guide in authentically representing disease.

Aspen Pharmacare posted a 5% rise in half-year earnings on Monday and said it expects double-digit revenue and core profit growth in its commercial pharmaceuticals unit in the full year, benefiting from its Latin American portfolio and the roll-out of its weight-loss drug Mounjaro.